Adma Biologics reported $528.2M in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
Adma Biologics USD 528.2M 17.03M Jun/2026
Alnylam Pharmaceuticals USD 4.62B 400.86M Jun/2026
BioCryst Pharmaceuticals USD 484.68M 111.06M Jun/2026
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Novavax USD 771.1M 79.72M Jun/2026
Omeros USD 69.65M 26.53M Jun/2025
Takeda JPY 3.15T 59.77B Jun/2026